Autologous CD7 CAR T-cell

Autologous CD7 CAR T-cell therapy is a type of immunotherapy that involves genetically modifying a patient's own (autologous) T cells to express a chimeric antigen receptor (CAR) specifically designed to target the CD7 protein. CD7 is a transmembrane glycoprotein highly expressed on the surface of malignant T cells in various T-cell leukemias and lymphomas, such as T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), and also in some acute myeloid leukemia (AML) cases. The CAR construct enables the modified T cells to recognize and bind to CD7-expressing cancer cells, leading to their destruction. A key challenge with CD7-targeted CAR T-cells is "fratricide," where the CAR T-cells might attack each other due to CD7 expression on normal T cells. To overcome this, strategies like gene editing (e.g., CRISPR/Cas9 to knock out CD7 expression on the CAR T-cells themselves) or using an endoplasmic reticulum anchor domain to prevent CD7 expression on the CAR T-cell surface are employed. This therapy aims to provide a novel treatment option for relapsed or refractory T-cell malignancies, which often have a poor prognosis. The manufacturing process involves collecting the patient's T cells via leukapheresis, genetically engineering them with the CAR construct, expanding them in vitro, and then reinfusing them back into the patient. [4, 5, 8, 9, 11, 15, 17, 18, 20, 24, 25]

Other names

CD7-targeted autologous CAR T-cell therapyCD-7-targeted autologous CAR T-cell therapyCD 7-targeted autologous CAR T-cell therapy